Latest Healthcare News

Page 2 of 182
CONNEQT Health reported a 40% revenue increase to $2.28 million for the half-year ending December 2025, driven by strong sales of its CONNEQT Pulse device and early subscription uptake. Despite narrowing its net loss by 14%, the company continues to navigate operational restructuring and funding challenges as it pivots towards a recurring revenue model.
Ada Torres
Ada Torres
27 Feb 2026
PainChek Limited reported a half-year loss of AUD 4.7 million but achieved a major regulatory milestone with FDA clearance for its Adult App, unlocking significant US market opportunities. The company also completed a share consolidation and raised capital to support growth.
Ada Torres
Ada Torres
27 Feb 2026
Radiopharm Theranostics reported a 44% increase in net loss to $27 million for the half-year ended December 2025, driven by expanded R&D spending. The company bolstered its cash reserves through a $35 million placement while progressing multiple clinical trials across its radiopharmaceutical pipeline.
Ada Torres
Ada Torres
27 Feb 2026
Racura Oncology reported a $4.1 million loss for H1 FY26, reflecting heavy investment in clinical trials and intellectual property. The company also boosted cash reserves through capital raises and rebranded from Race Oncology.
Ada Torres
Ada Torres
27 Feb 2026
ECS Botanics has reported a return to profitability and positive cash flow in the first half of FY26, driven by a strategic shift to branded products and major infrastructure expansion.
Ada Torres
Ada Torres
27 Feb 2026
IMEXHS Limited delivered FY25 results at the top end of guidance, reporting a 10% revenue increase and a tripling of underlying EBITDA. The company’s software and radiology services both showed solid growth, setting the stage for an optimistic FY26 outlook.
Ada Torres
Ada Torres
27 Feb 2026
Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.
Ada Torres
Ada Torres
27 Feb 2026
Clarity Pharmaceuticals has reported a steep 136% increase in its half-year loss to $55.6 million, alongside the closure of its European subsidiary, signaling a challenging period for the ASX-listed biotech.
Ada Torres
Ada Torres
27 Feb 2026
Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.
Ada Torres
Ada Torres
27 Feb 2026
Anteris Technologies Global Corp. posted a $94.2 million loss for 2025 amid a 29% revenue decline, while progressing its pivotal DurAVR THV clinical trial and securing $320 million in early 2026 financings.
Ada Torres
Ada Torres
27 Feb 2026
Entropy Neurodynamics reports a 14.8% reduction in half-year losses while progressing a pioneering clinical trial for Binge Eating Disorder using its proprietary psychedelic drug TRP-8803. The company also secured $6.1 million in new funding and strategic collaborations to enhance its neuropsychiatry platform.
Ada Torres
Ada Torres
27 Feb 2026
Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.
Ada Torres
Ada Torres
27 Feb 2026